User:Mr. Ibrahem/Ponatinib

Ponatinib, sold under the brand name Iclusig, is a medication used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) which is Philadelphia chromosome–positive (Ph+). It is used when other treatments have failed. It is taken by mouth.

Common side effects include pneumonia, pancreatitis, fever, abdominal pain, heart attack, atrial fibrillation, low platelets, low neutrophils, stroke, kidney problems, and heart failure. Serious blood clots occur in arteries in about 25% of people and veins in about 5% of people. It is a tyrosine-kinase inhibitor which blocks Bcr-Abl.

Ponatinib was approved for medical use in the United States in 2012 and Europe in 2013. In the United Kingdom it costs the NHS about £5,100 per month. This amount in the United States is about 19,000 USD.